Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in Follicular Lymphoma Not Accomplishing Complete Response With Upfront Therapy
NCT06510361Phase 2Recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab in follicular lymphoma (FL), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Complete Response Rate at 12 months. Started Nov 2024; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06510361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510361.